Phase 3 N=1,752 Randomized Trial: Maternal Vitamin D Supplementation to Prevent Childhood Asthma (VDAART)
Asthma
Primary: Asthma or Recurrent Wheeze in First 3 Years of Life — 98; 120; 307; 281 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=151 Evaluation of Cardiovascular Risk Markers in Psoriasis Patients Treated With Secukinumab
Psoriasis
Primary: Flow Mediated Dilation (FMD) at Week 12 Followed by Secukinumab 300 mg vs Pooled Placebo Treatment — 5.23; 3.65 Percentage maximal increase in diameter — p=0.2230
Phase 3 N=385 Safety and Efficacy of EXE844 Otic Suspension in Otitis Media at Time of Tympanostomy Tube Insertion (OMTT)
Otitis Media With Effusion in Children · Otitis Media Recurrent
Primary: Percentage of Subjects With Sustained Clinical Cure at Day 8 — 76.2; 71.8; 56.8 percentage of participants
Phase 3 N=8 Phase III Study of ISU302 in Patients With Type 1 Gaucher Disease
Gaucher Disease, Type 1
Primary: The Difference in Hemoglobin Concentration [g/dL] — 9.49; 11.44 g/dL
Phase 3 N=742 Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Diffuse Large B-cell Lymphoma
Primary: Disease-free Survival (DFS) — 77.8; 77.0 Percentage of participants — p=0.276
Phase 3 N=308 Immune Response Post Pry Vaccination of 2 Formulations of DTPw-HBV Vaccine Given With Rotavirus Vaccine to Infants
Hepatitis B
Primary: Seroprotection Status for Anti-diphteria (Anti-DT) Antibodies — 100; 100; 100; 100 IU/mL
Phase 3 N=1,014 Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications
Type 2 Diabetes Mellitus
Primary: Change in HbA1c From Baseline to Week 26 — -0.89; -0.91 percentage of hemoglobin
Phase 3 N=234 A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
Tardive Dyskinesia
Primary: Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score Change From Baseline at Week 6 — -0.1; -3.2; -1.9 scores on a scale — p=<0.0001
Phase 3 N=495 Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2)
Cachexia · Non-Small Cell Lung Cancer
Primary: Change in Lean Body Mass — 0.65; -0.98 kg — p=< 0.0001
Phase 3 N=513 Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Cachexia · Non-Small Cell Lung Cancer
Primary: Percentage of Participants With Treatment-emergent Adverse Events — 52; 56 percentage of participants
Phase 3 N=36 A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Adults With Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis
Chronic Hepatitis C · Decompensated Cirrhosis · Hepatitis C Virus
Primary: Percentages of Participants With Sustained Virologic Response 12 Weeks Post-Treatment (SVR12) in Group 1 and in Group 2 — 100; 95.8 percentage of participants
Phase 3 N=484 Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1)
Cachexia · Non-Small Cell Lung Cancer
Primary: Change in Lean Body Mass — 0.99; -0.47 kg — p=< 0.0001
Phase 3 N=158 12-Month Open-Label Long-term Safety Study of TNX-102 SL Tablets in Fibromyalgia Patients
Primary Fibromyalgia
Primary: Newly-emergent Adverse Events (NEAEs) During Treatment With TNX-102 SL Tablets Taken Daily at Bedtime Over 12 Months in Patients With Fibromyalgia. — 60; 54; 18; 9…
Phase 3 N=99 Aripiprazole Effects on Alcohol Drinking and Craving
Alcohol Dependence
Primary: Total Number of Drinks Per Day During Natural (Usual Environment) Conditions — 5.8; 6.4 standard drinks
Phase 3 N=305 Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024)
Non-Small Cell Lung Carcinoma
Primary: Progression Free Survival (PFS) Rate at Month 6 — 62.1; 50.3 Percentage of Participants — p=<0.001